MIM
BMRN icon

Macroview Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Macroview Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-126
Closed -$8.86K – 146
2024
Q3 		$8.86K Buy
+126
New +$10.5K 0.01% 271
2023
Q4 		– Sell
-12
Closed -$1.06K – 647
2023
Q3 		$1.06K Buy
+12
New +$1.07K ﹤0.01% 653
2019
Q4 		– Sell
-48
Closed -$3K – 303
2019
Q3 		$3K Buy
+48
New +$3.7K 0.01% 222

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Macroview Investment Management's BMRN Position: Q4 2024 in Review

Macroview Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 126 shares — an estimated $8.86K sold.

Macroview Investment Management first reported a position in BMRN in Q3 2019 and held it in 3 quarters. The position peaked at $8.86K in Q3 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Macroview Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 126 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $8.86K.
  • Macroview Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Macroview Investment Management's BioMarin Pharmaceuticals position peaked at $8.86K in Q3 2024.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.